分泌抗 EpCAM 双特异性 T 细胞衔接器的 CAR T 细胞克服靶向上皮来源癌时的肿瘤异质性
CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas.
嵌合抗原受体(CAR)T细胞疗法治疗实体瘤的成功有限,部分原因是肿瘤异质性和抗原逃逸。
ALL SOURCES
CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas.
嵌合抗原受体(CAR)T细胞疗法治疗实体瘤的成功有限,部分原因是肿瘤异质性和抗原逃逸。
Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy.
肝细胞癌(HCC)是最常见的原发性肝癌,其特征为诊断偏晚、治疗效果有限以及高度免疫抑制的肿瘤微环境。
Integrated therapies for targeting the microenvironment of hepatocellular carcinoma.
肝细胞癌(HCC)微环境(MEs)由免疫和非免疫成分组成,这些成分驱动肿瘤进展和治疗耐药。
Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.
对 195 例肝细胞癌患者肝活检标本的免疫组化显示,82.6% 为 GPC3 阳性。
Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood.
IDRA HBV-TCR T 细胞可在 Tacrolimus 和 MMF 存在下裂解全血中游离的 HBV-HCC 细胞。
Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma.
肉瘤是一组多样化的骨和软组织肿瘤,占儿童癌症的10%以上。
共 6 条
MEMBER ACCOUNT
登录成功会直接打开下一页。